Vident Advisory LLC Makes New Investment in Bausch + Lomb Corporation $BLCO

Key Points

• Vident Advisory LLC invested approximately $289,000 in Bausch + Lomb Corporation, acquiring 19,898 shares during the 1st quarter, as reported in their Form 13F filing.
• Multiple institutional investors increased their holdings in Bausch + Lomb, with National Bank of Canada boosting its stake by 101.7% in the same period.
• Analysts have mixed views on the stock, with target price adjustments ranging from $12.00 to $19.00 and a consensus rating of "Hold" despite three analysts rating it as a Buy.

Vident Advisory LLC acquired a new position in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,898 shares of the company's stock, valued at approximately $289,000.

A number of other large investors also recently added to or reduced their stakes in BLCO. Deutsche Bank AG acquired a new position in Bausch + Lomb during the first quarter worth $50,750,000. Allianz Asset Management GmbH acquired a new stake in shares of Bausch + Lomb in the first quarter valued at about $4,712,000. Alberta Investment Management Corp raised its position in shares of Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company's stock valued at $47,360,000 after buying an additional 258,000 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Bausch + Lomb in the first quarter valued at about $1,450,000. Finally, Tang Capital Management LLC raised its position in shares of Bausch + Lomb by 28.6% in the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company's stock valued at $8,127,000 after buying an additional 100,000 shares during the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Trading Up 0.2%

Bausch + Lomb stock traded up $0.04 during midday trading on Monday, hitting $15.23. 355,784 shares of the stock were exchanged, compared to its average volume of 478,713. Bausch + Lomb Corporation has a fifty-two week low of $10.45 and a fifty-two week high of $21.69. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of -19.52, a PEG ratio of 1.55 and a beta of 0.63. The stock's 50-day simple moving average is $14.35 and its 200 day simple moving average is $13.40. The company has a current ratio of 1.55, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. Bausch + Lomb's revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Citigroup increased their target price on shares of Bausch + Lomb from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Wells Fargo & Company increased their target price on shares of Bausch + Lomb from $12.00 to $15.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Barclays reduced their target price on shares of Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating for the company in a research report on Monday, June 9th. Evercore ISI increased their target price on shares of Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Morgan Stanley increased their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $15.56.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.